Aldosterone Antagonism and Microvascular Function

Hypertension Clinical Trial

Official title:

Effects of Aldosterone Antagonism on Insulin-mediated Microvascular Function in Subjects With the Metabolic Syndrome

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01887119
• Other study ID #: 133031
• Status: Terminated
• Phase: Phase 4
• Start date: October 2013
• Est. completion date: November 2018

Study information

• Verified date: November 2018
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The prevalence of obesity and obesity-related complications is currently taking epidemic proportions. These complications increase the risk of type 2 diabetes and cardiovascular disease, which are important causes of morbidity and mortality worldwide.

It is important to gain insight in the mechanisms underlying obesity-related complications, because this may lead to the development of directed therapeutic strategies.

Currently, there is significant evidence that the cause of both insulin resistance and hypertension must be sought at the level of the microcirculation.

Over activity of the renin-angiotensin-aldosterone system is a potential cause of microvascular dysfunction. Angiotensin II was indeed found to be implicated in the pathogenesis of obesity-associated hypertension and insulin resistance, possibly through interference with the vascular effects of insulin.

Increased aldosterone levels have also been associated with resistant hypertension and insulin resistance, which is illustrated in patients with primary aldosteronism. Furthermore, aldosterone is known to exert several detrimental effects on the vasculature, some of which are offset by mineralocorticoid receptor antagonists.

In obese individuals, plasma aldosterone concentrations are increased as well. We hypothesize that increased aldosterone levels in adipose persons induce microvascular dysfunction, which contributes to the development of insulin resistance and hypertension, and mineralocorticoid receptor antagonism results in improved insulin sensitivity and decreased blood pressure by counteracting the adverse effects of aldosterone on the microvasculature.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: November 2018
• Est. primary completion date: November 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age 40-65 years

• Caucasian

• Waist circumference > 102 cm (men)/> 88 cm (women)

• Triglycerides > 1.7 mmol/L

• High-normal blood pressure (office blood pressure: 130/85 - 139/89 mm Hg) or stage I hypertension (office blood pressure: 140/90 mm Hg - 159/99 mm Hg; 24h ABPM: 125/80 - 149/89 mm Hg)

Exclusion Criteria:

• Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death)

• Diabetes mellitus/impaired glucose metabolism (fasting glucose values > 5.6 mmol/L)

• Grade 2 or 3 hypertension (office blood pressure: > 160/100 mm Hg; ABPM > 150/90 mm Hg)

• Unstable or severe pulmonary disease

• Unstable or severe thyroid disorders

• Inflammatory diseases

• Alcohol use > 2 U/day (women)/> 3 U/day (men)

• Use of antihypertensive, lipid-lowering or glucose-lowering medications,

• Use of corticosteroids, medication known to inhibit or induce CYP3A4, lithium, and tricyclic antidepressants or antipsychotic medication, and regular use (weekly or several times a week) of NSAIDs

• Plasma potassium levels < 3.2 mmol/L or > 5 mmol/L

• eGFR < 60 mL/min

• Impairment of hepatic function

• Pregnancy or lactation

Related Conditions & MeSH terms

• Abdominal Obesity Metabolic Syndrome
• Hypertension
• Insulin Resistance
• Metabolic Syndrome X
• Obesity, Abdominal
• Syndrome

Intervention

Drug:
• Eplerenone

Other:
• Placebo
Eplerenone-matched placebo

Locations

Country	Name	City	State
Netherlands	Maastricht University	Maastricht	Limburg

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in capillary recruitment (insulin-induced increase in microvascular blood volume in skeletal muscle) from baseline after 4 weeks of Eplerenone treatment or placebo	The difference in microvascular blood volume in skeletal muscle of the forearm, which is assessed with contrast enhanced ultrasound, before and during a hyperinsulinemic, euglycemic clamp (performed to determine insulin sensitivity)	Change from baseline after 4 weeks of treatment with either Eplerenone or placebo